Table: Towa Pharmaceutical -6-MTH group results
Nov 9 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2016 Sep 30, 2015 Mar 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 40.52 39.16 88.40
(+3.5 pct) (+17.0 pct) (+7.7 pct)
Operating 2.32 5.52 7.20
(-57.9 pct) (+32.0 pct) (-35.3 pct)
Recurring 383 mln 5.61 5.10
(-93.2 pct) (+1.1 pct) (-49.8 pct)
Net 85 mln 4.01 3.60
(-97.9 pct) (-1.3 pct) (-53.2 pct)
EPS 5.21 yen 239.07 yen 219.47 yen
EPS Diluted 4.61 yen 229.96 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 47.50 yen
-Q4 div 47.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results